Diana Ernst, RPh

Most Recent Articles by Diana Ernst, RPh

AGS: Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Updated

AGS: Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Updated

By

Over 1400 clinical trials and research studies were reviewed by a panel of 13 experts to develop the new guideline.

Tanezumab Beneficial in Second Phase 3 Osteoarthritis Pain Trial

Tanezumab Beneficial in Second Phase 3 Osteoarthritis Pain Trial

By

Tanezumab is a humanized monoclonal antibody that selectively targets, binds to, and inhibits nerve growth factor (NGF).

FDA Panel Votes on Novel Osteoporosis Treatment Evenity

FDA Panel Votes on Novel Osteoporosis Treatment Evenity

By

In the Biologics License Application (BLA) resubmission, Amgen and UCB proposed to narrow the indication to treatment of osteoporosis in postmenopausal women at high risk of fracture.

Celiprolol Granted Priority Review From FDA for Ehlers-Danlos Syndrome

Celiprolol Granted Priority Review From FDA for Ehlers-Danlos Syndrome

By

Vascular EDS is the most severe subtype of Ehlers-Danlos syndrome where patients suffer from life-threatening arterial dissections and ruptures, as well as intestinal and uterine ruptures.

Rituxan Labeling Updated With Follow-Up Treatment Info for Patients With GPA/MPA

Rituxan Labeling Updated With Follow-Up Treatment Info for Patients With GPA/MPA

By

The FDA has approved updated labeling for Rituxan to include information on follow up treatment for patients with GPA and MPA who have achieved disease control with induction therapy.

More Articles by Diana Ernst, RPh

Sign Up for Free e-newsletters